Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

Jan P. Deroose, Dirk J. Grünhagen, Alexander M.M. Eggermont, Cornelis Verhoef

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

15 Citaten (Scopus)

Samenvatting

In-transit metastases of melanoma occur in 5-8% of all melanoma patients. In case of extensive locoregional disease, Tumor necrosis factor-α and melphalan-based isolated limb perfusion (TM-ILP) had proven to yield excellent local control. Here, we report on repeat TM-ILP for locoregional recurrence after isolated limb perfusion. Between 1991 and 2013, 37 consecutive repeat TM-ILPs were analyzed in 32 different patients. Three patients underwent a third TM-ILP. During a median follow-up of 20 months after repeat TM-ILP, the overall response rate was 86%. Complete response (CR) was recorded after 24 TM-ILPs (65%). CR after first TM-ILP was a strong predictor for successful repeat TM-ILP in terms of clinical response and local recurrence. Local toxicity was mild (70% Wieberdink I-II). The local recurrence rate was 59%. Five-year overall survival was 35%. Repeat TM-ILP is a safe treatment modality in melanoma patients with recurrent in-transit metastases of melanoma. Those with a CR after first TM-ILP benefit the most from repeat TM-ILP.

Originele taal-2Engels
Pagina's (van-tot)427-431
Aantal pagina's5
TijdschriftMelanoma Research
Volume25
Nummer van het tijdschrift5
DOI's
StatusGepubliceerd - 18 sep. 2015
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases'. Samen vormen ze een unieke vingerafdruk.

Citeer dit